Erlotinib monotherapy for maintenance treatment of non-small-cell lung cancer

  • Technology appraisal guidance
  • TA227
  • Published: 

Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (monotherapy): appeal

An appeal has been lodged for this appraisal. Below are the papers related to this appeal.

For more information on the Technology Appraisal Appeal Process, go to the appeal hearings homepage.

This page was last updated: 29 June 2011